0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > GM-CSF

GM-CSF

Brief Information

Name:Macrophage colony stimulating factor 2
Target Synonym:GM-CSF,Molgramostin,CSF2,Colony Stimulating Factor 2,Sargramostim,GMCSF,CSF,Granulocyte Macrophage-Colony Stimulating Factor,Granulocyte-Macrophage Colony Stimulating Factor,Colony-Stimulating Factor,Granulocyte-Macrophage Colony-Stimulating Factor,Colony Stimulating Factor 2 (Granulocyte-Macrophage),Molgramostim
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-GMFH28-Cell-based assay
 GM-CSF CELL

GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) stimulates proliferation of TF-1 cells. The specific activity of GMP Human GM-CSF Protein is > 5.00ⅹ10^6 IU/mg, which is calibrated against human GM-CSF WHO International Standard (NIBSC code: 88/646) (QC tested).

GMF-H4214-Cell-based assay
 GM-CSF CELL

Human GM-CSF, premium grade (Cat. No. GMF-H4214) stimulates proliferation of TF-1 cells. The specific activity of Human GM-CSF, premium grade is > 5.00ⅹ10^6 IU/mg, which is calibrated against human GM-CSF WHO International Standard (NIBSC code: 88/646) (QC tested).

GMF-H8214-BLI
 GM-CSF BLI

Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (SPR verified) (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

GMF-H4214-BLI
 GM-CSF BLI

Loaded Human GM-CSF R alpha, Fc Tag (Cat. No. GRA-H5255) on Protein A Biosensor, can bind Human GM-CSF, premium grade (Cat. No. GMF-H4214) with an affinity constant of 16.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

GM-CSF,CSF2,MGC131935

Background

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Otilimab MOR-04357; GSK-3196165; GSK-165; MOR-103 Phase 3 Clinical University Of Melbourne Stomach Neoplasms; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Spondylarthritis; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Osteoarthritis Details
Plonmarlimab TJM-2; TJ-003234; TJ-003234RAR101 Phase 3 Clinical I-Mab Biopharma Co Ltd Macrophage Activation Syndrome; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Arthritis, Gouty; Lymphohistiocytosis, Hemophagocytic Details
Pexastimogene devacirepvec TG-6006; JX-594 Phase 3 Clinical Sillajen Inc, National Cancer Institute, Samsung Medical Center & Samsung Electronics Devices Llc Sarcoma, Ewing; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Neuroblastoma; Liver Neoplasms; Neoplasms; Wilms Tumor; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours; Ovarian Neoplasms; Rhabdomyosarcoma Details
Gemogenovatucel-T IND-14205 Phase 3 Clinical Gradalis Inc Ovarian Neoplasms; Liver Neoplasms; Colonic Neoplasms; Breast Neoplasms; Sarcoma, Ewing; Peritoneal Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Vusolimogene oderparepvec RP-1 Phase 3 Clinical Replimune Group Inc Skin Melanoma; Mismatch Repair Deficient Cancer; Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Skin Neoplasms; Neoplasms; Microsatellite Instability; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Namilumab MT-203; AMG-203; IZN-101 Phase 2 Clinical Takeda Pharmaceutical Co Ltd, Amgen Inc Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Sarcoidosis; Psoriasis; Sarcoidosis, Pulmonary Details
PBI-1402 PBI-1402 Phase 2 Clinical Prometic Life Sciences Anemia Details
BT-001 BT-001 Phase 2 Clinical Transgene Sa Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Gimsilumab MORAb-022; KIN-1901 Phase 2 Clinical Morphotek Inc Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Rheumatic Diseases; Inflammation Details
MEDI-5395 MEDI-5395; MEDI5395 Phase 1 Clinical Medimmune Solid tumours Details

This web search service is supported by Google Inc.

totop

Laisser un message